Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions
- 21 May 2008
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 99 (7) , 1311-1318
- https://doi.org/10.1111/j.1349-7006.2008.00836.x
Abstract
Systemic therapy is an integral part of the management of non-keratinizing nasopharyngeal carcinoma (NPC). The purposes of this review are to provide the latest results and future directions of clinical and translational research for this disease, and to illustrate how some of these new therapies have improved the treatment outcome for patients with NPC. Particular attention will be paid to the clinical application of chemotherapy in the adjunctive treatment of locoregionally advanced NPC, novel targeted drugs, Epstein-Barr virus-targeted vaccine therapies, and the use of plasma Epstein-Barr virus DNA as a biomarker for selecting patients for adjunctive therapies.This publication has 86 references indexed in Scilit:
- Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trialEuropean Journal Of Cancer, 2007
- Analysis of Epstein–Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assaysJournal of General Virology, 2006
- Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaJournal of Clinical Oncology, 2005
- Long-Term Survival After Cisplatin-Based Induction Chemotherapy and Radiotherapy for Nasopharyngeal Carcinoma: A Pooled Data Analysis of Two Phase III TrialsJournal of Clinical Oncology, 2005
- Concurrent and Adjuvant Chemotherapy for Nasopharyngeal Carcinoma: A Factorial StudyJournal of Clinical Oncology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in TumorsJournal of Clinical Oncology, 2004
- Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal CarcinomaJNCI Journal of the National Cancer Institute, 2002
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinomaHead & Neck, 2001